Category: Greatbatch Inc.
Greatbatch says it might spin out its Algostim spinal cord stimulation subsidiary as a publicly traded company.
Here's a look at some of the top Wall Street stories for medical device companies this week: FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried; Greatbatch acquires Uruguay's CCC Medical Devices; T2 Biosystems IPO raises $57M for MRI-based diagnostics; Strong Q4, $750M buyback give CareFusion a boost; Baxano: Strong Q2, new patents can't appease Wall Street
Greatbatch says it paid an unspecified amount for CCC Medical Devices, a Uruguay-based maker of implantable pulse generators, programmer systems, battery chargers, patient wands and leads.
Greatbatch (NYSE:GB) said today that it paid an unspecified amount to acquire a Uruguayan medical device company.
Sunshine Heart taps ex-Boston Scientific cardiovascular R&D veteran Brian Brown as its new vice president for operations & technology.
Greatbatch says it plans to move some of its U.S. manufacturing operations to plants in Tijuana, Mexico, and from Oregon to Massachusetts.
Greatbatch (NYSE:GB) said today that it's planning to shuffle its manufacturing operation, moving some production from Minnesota, Oregon and Massachusetts to plants in Tijuana, Mexico.
Greatbatch files for European CE Mark for its spinal cord stimulation system, hoping to land marketing approval the treatment of chronic pain of the trunk and limbs.
Greatbatch (NYSE:GB) filed a CE Mark application for its spinal cord stimulation system with German notified body TÜV SÜD America.
Greatbatch files a pre-market approval application for its spinal cord neuromodulation system for treatment of chronic pain of the trunk and limbs.
Greatbatch (NYSE:GB) this week filed a pre-market approval application with the FDA for its spinal cord neuromodulation system.
The neuromodulation system comes from the Frisco, Texas-based company's subsidiary, QiG Group, which hopes to win indication to treat chronic pain of the trunk and limbs.